CYAD - Celyad Oncology highlights new CAR T product gives data update

Celyad Oncology (CYAD) highlights new preclinical allogeneic armored CAR T candidate developed from its shRNA platform.The submission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate, expected in mid-2022.The company also provided data updates on its CYAD-211 and CYAD-101 products at its research and development day.Early-stage trial of CYAD-211 in certain patients with myeloma showed dose dependent engraftment up to dose level three (300×106 cells per infusion) with no Graft-versus-Host disease reported to date.CYAD-101 following FOLFIRI preconditioning in advanced metastatic colorectal cancer ((mCRC)) was well-tolerated.Cell kinetic and activity of alloSHRINK trial support the initiation of the KEYNOTE-B79 Phase 1b trial of CYAD-101 following FOLFOX preconditioning chemotherapy during early fourth quarter 2021.The company had presented early-stage data from blood cancer trial for CYAD-211, last month.

For further details see:

Celyad Oncology highlights new CAR T product, gives data update